Table II.
Clinical trials investigating immune checkpoint inhibitors combination therapy in hepatocellular carcinoma.
| Author, year | Therapy method | Trial ID | Phase | Patients number | Lines of therapy | Endpoint | Status | (Refs.) |
|---|---|---|---|---|---|---|---|---|
| Qin et al, 2018 | Camrelizumab + Apatinib | NCT02942329 | I | 14 | Second-line | ORR | Recruiting | (52) |
| Pishvaian et al, 2018 | Atezolizumab + Bevacizumab | NCT02715531 (GO30140) | IB | 23 | Second-line | ORR/DCR | Recruiting | (56) |
| Qin et al, 2020 | Atezolizumab + Bevacizumab | NCT03434379 | III | 480 | First-line | OS/PFS | Recruiting | (58) |
| Llovet et al, 2019 | Pembrolizumab + Lenvatinib | NCT03006926 | I | 104 | Second-line | DLT/AEs | Recruiting | (62) |
| Yau et al, 2019 | Nivolumab + Ipilimumab | NCT01658878 (cohort 4) | I/II | 148 | Second-line | AEs | Recruiting | (66) |
| Abou-Alfa et al, 2018 | Durvalumab + Tremelimumab | NCT03298451 (HIMALAYA) | III | 1,350 | First-line | OS | Recruiting | (69) |
OS, overall survival; PFS, progression-free survival; DCR, disease control rate; ORR, objective response rate; AEs, adverse events.